company background image
CDMO logo

Avid Bioservices NasdaqCM:CDMO Stock Report

Last Price

US$12.30

Market Cap

US$788.7m

7D

-0.3%

1Y

88.9%

Updated

20 Dec, 2024

Data

Company Financials +

Avid Bioservices, Inc.

NasdaqCM:CDMO Stock Report

Market Cap: US$788.7m

CDMO Stock Overview

Operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. More details

CDMO fundamental analysis
Snowflake Score
Valuation2/6
Future Growth1/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Rewards

Revenue is forecast to grow 19.65% per year

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years


My Notes

Capture your thoughts, links and company narrative

Avid Bioservices, Inc. Competitors

Intercept Pharmaceuticals

NasdaqGS:ICPT

US$794.7m

Gyre Therapeutics

NasdaqCM:GYRE

US$914.9m

Immatics

NasdaqCM:IMTX

US$821.2m

Zymeworks

NasdaqGS:ZYME

US$935.4m

Price History & Performance

Summary of share price highs, lows and changes for Avid Bioservices
Historical stock prices
Current Share PriceUS$12.30
52 Week HighUS$12.48
52 Week LowUS$5.65
Beta1.41
1 Month Change0.65%
3 Month Change6.03%
1 Year Change88.94%
3 Year Change-58.36%
5 Year Change52.61%
Change since IPO-37.24%

Recent News & Updates

Recent updates

Is Avid Bioservices (NASDAQ:CDMO) Using Too Much Debt?

Aug 26
Is Avid Bioservices (NASDAQ:CDMO) Using Too Much Debt?

Avid Bioservices, Inc. (NASDAQ:CDMO) Surges 43% Yet Its Low P/S Is No Reason For Excitement

Jul 29
Avid Bioservices, Inc. (NASDAQ:CDMO) Surges 43% Yet Its Low P/S Is No Reason For Excitement

There's No Escaping Avid Bioservices, Inc.'s (NASDAQ:CDMO) Muted Revenues Despite A 40% Share Price Rise

Mar 07
There's No Escaping Avid Bioservices, Inc.'s (NASDAQ:CDMO) Muted Revenues Despite A 40% Share Price Rise

We Think Avid Bioservices (NASDAQ:CDMO) Has A Fair Chunk Of Debt

Feb 28
We Think Avid Bioservices (NASDAQ:CDMO) Has A Fair Chunk Of Debt

There's No Escaping Avid Bioservices, Inc.'s (NASDAQ:CDMO) Muted Revenues Despite A 39% Share Price Rise

Dec 28
There's No Escaping Avid Bioservices, Inc.'s (NASDAQ:CDMO) Muted Revenues Despite A 39% Share Price Rise

Does Avid Bioservices (NASDAQ:CDMO) Have A Healthy Balance Sheet?

Nov 10
Does Avid Bioservices (NASDAQ:CDMO) Have A Healthy Balance Sheet?

Calculating The Intrinsic Value Of Avid Bioservices, Inc. (NASDAQ:CDMO)

Oct 15
Calculating The Intrinsic Value Of Avid Bioservices, Inc. (NASDAQ:CDMO)

Time To Worry? Analysts Are Downgrading Their Avid Bioservices, Inc. (NASDAQ:CDMO) Outlook

Jun 23
Time To Worry? Analysts Are Downgrading Their Avid Bioservices, Inc. (NASDAQ:CDMO) Outlook

Is Avid Bioservices (NASDAQ:CDMO) Using Too Much Debt?

Jun 12
Is Avid Bioservices (NASDAQ:CDMO) Using Too Much Debt?

Little Excitement Around Avid Bioservices, Inc.'s (NASDAQ:CDMO) Earnings As Shares Take 26% Pounding

May 21
Little Excitement Around Avid Bioservices, Inc.'s (NASDAQ:CDMO) Earnings As Shares Take 26% Pounding

Are Investors Undervaluing Avid Bioservices, Inc. (NASDAQ:CDMO) By 49%?

May 12
Are Investors Undervaluing Avid Bioservices, Inc. (NASDAQ:CDMO) By 49%?

Does Avid Bioservices (NASDAQ:CDMO) Have A Healthy Balance Sheet?

Mar 13
Does Avid Bioservices (NASDAQ:CDMO) Have A Healthy Balance Sheet?

Here's Why Avid Bioservices (NASDAQ:CDMO) Has A Meaningful Debt Burden

Nov 10
Here's Why Avid Bioservices (NASDAQ:CDMO) Has A Meaningful Debt Burden

Avid Bioservices GAAP EPS of $0.02 beats by $0.01, revenue of $36.7M beats by $3.26M

Sep 06

Shareholder Returns

CDMOUS BiotechsUS Market
7D-0.3%-5.6%-3.5%
1Y88.9%-1.5%22.1%

Return vs Industry: CDMO exceeded the US Biotechs industry which returned -1.5% over the past year.

Return vs Market: CDMO exceeded the US Market which returned 22.1% over the past year.

Price Volatility

Is CDMO's price volatile compared to industry and market?
CDMO volatility
CDMO Average Weekly Movement5.3%
Biotechs Industry Average Movement10.7%
Market Average Movement6.3%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.1%

Stable Share Price: CDMO has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: CDMO's weekly volatility has decreased from 10% to 5% over the past year.

About the Company

FoundedEmployeesCEOWebsite
1981371Nick Greenwww.avidbio.com

Avid Bioservices, Inc. operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018.

Avid Bioservices, Inc. Fundamentals Summary

How do Avid Bioservices's earnings and revenue compare to its market cap?
CDMO fundamental statistics
Market capUS$788.67m
Earnings (TTM)-US$152.05m
Revenue (TTM)US$150.45m

5.2x

P/S Ratio

-5.2x

P/E Ratio

Is CDMO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CDMO income statement (TTM)
RevenueUS$150.45m
Cost of RevenueUS$138.89m
Gross ProfitUS$11.55m
Other ExpensesUS$163.60m
Earnings-US$152.05m

Last Reported Earnings

Oct 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.38
Gross Margin7.68%
Net Profit Margin-101.07%
Debt/Equity Ratio344.0%

How did CDMO perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 00:22
End of Day Share Price 2024/12/20 00:00
Earnings2024/10/31
Annual Earnings2024/04/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Avid Bioservices, Inc. is covered by 14 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Matthew HewittCraig-Hallum Capital Group LLC
Vernon BernardinoFBR Capital Markets & Co.
Joseph PantginisH.C. Wainwright & Co.